Global Partners L.P. (GLP)
NYSE NYSE Primary 
Hims & Hers Health: The Market Is Likely Wrong
Hims & Hers Health is undervalued despite impressive growth, with analysts overly focused on compounded GLP-1s and potential FDA restrictions. BoA's negative outlook contrasts with Hims' projected 90% YoY Q4 growth and strong non-GLP-1 business expansion. Hims' innovative product launches, such as meal replacement bars, highlight its focus on personalized health services and continuous growth potential.
GLP-1s and Brian Thompson's killing loom large at top health-care conference
Thousands of health-care executives descended on JPMorgan's annual health-care conference in San Francisco this week. The conference took place a month after UnitedHealthcare CEO Brian Thompson was fatally shot in New York City.
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (LLY -4.21%) Mounjaro skyrocketing over the past year. However, Eli Lilly recently surprised investors when it cut its full-year revenue guidance ahead of an investor conference after sales of its GLP-1 drugs fell short of expectations.
Dr. Kavita Patel talks impact of GLP-1 price negotiations
Dr. Kavita Patel joins 'Fast Money' to talk what is next for GLP-1 drug makers.
New Year's Resolutions: Lose Weight & Allocate to GLP-1 ETFs
For many of us, a new year often means a new chance to start fresh in our battle with weight. Thanks to interesting ETF product development, especially in the past year, it could also mean a chance to consider the investment opportunity in weight loss as a theme.
Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval
Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / ACCESSWIRE / January 15, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that it has received the necessary independent ethics board approval required for its contract research organization ("CRO") to begin to implement and execute human pilot study GLP-1-H25-5 (the "Study"). The Study will compare an oral version of liraglutide, formulated from the DehydraTECH-processing of Saxenda® ("DehydraTECH-liraglutide") to the conventional injected liraglutide (Saxenda®).
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024.
Tiziana Life Sciences' foralumab reduces side effects of discontinuing GLP-1 agonists
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its intranasal anti-CD3 monoclonal antibody, foralumab, has demonstrated the ability to mitigate the side effects associated with the discontinuation of GLP-1 agonists, medicines used to manage Type 2 diabetes and obesity. GLP-1 agonists, such as semaglutide marketed under brand names like Ozempic and Wegovy, are integral in treating metabolic disorders but often lead to side effects including sarcopenia and bone density loss.
GLP-1 makers could be under pressure in 2025
Jared Holz, Mizuho, joins 'Fast Money' to talk what is next for the obesity drug makers in 2025.
Cramer's Mad Dash: Cornell report on GLP-1s shows decrease in consumption of savory snacks
CNBC's Jim Cramer reports on a study from Cornell and its impact on the stock market.
Should You Buy the Dip in Novo Nordisk Stock Right Now?
The biggest talking point in the pharmaceutical industry at the moment revolves around treatments known as glucagon-like peptide-1 (GLP-1) agonists. GLP-1 agonists are used to treat diabetes and chronic weight management, although research suggests these medications could have other applications in areas such as sleep apnea, kidney disease, and cardiovascular complications.
Novo Nordisk is 'losing its pep' in GLP-1 race: BMO analyst
Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital Markets cut its price target on the pharmaceutical company from $156 to $105 per share. "This was supposed to be Novo's answer to Tirzepatide and Retatrutide, some higher efficacy drugs, and it kind of feels like where no man's land here.
